RBM22 and cancer: DHX8, EIF3G, RBM22, U2AF1 UPF1 and YBX-1 are also candidates therapeutic targets for cancer therapy because the tumor cell progression was strongly inhibited by the downregulation of these RBPs in cancer cells, including HCT116, SUIT2 and OE33 cells, but not in non-cancerous cells.